Skip to main content
Erschienen in: Supportive Care in Cancer 8/2023

01.08.2023 | Research

Drivers and barriers to COVID-19 vaccination in Australians with cancer

verfasst von: Christie Allan, Amelia Hyatt, Amanda Appathurai, Megan Crane, Chhay Lim, Rachel Woolstencroft, Monica A. Slavin, Amanda Piper, Danielle Spence, Benjamin W. Teh

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To understand the drivers and barriers for COVID-19 vaccination in people with cancer in Australia.

Methods

A cross-sectional, online survey, distributed nationally following the establishment of community vaccination programs, wider availability of COVID-19 vaccines and emergence of new variants. Consisting of 21 questions, the survey was designed to determine the behavioural and social drivers of vaccination, participant demographics, underlying disease and treatment, and vaccination status. It was open from the 10th of August 2021 to the 7th of September 2021, recruiting people who had a previous history of cancer (diagnosed or treated in the past 5 years).

Results

A total of 1506 responses were included in the final analysis. Overall, 87.8% reported a positive attitude toward vaccination and 83.1% had received at least one dose of a COVID-19 vaccine. Perceived risk of COVID-19 infection (for self and others) and engagement with a trusted health professional were key drivers for vaccination, while concerns about vaccine development, safety and side effects were barriers. Concerns about vaccination mostly stemmed from a place of misinformation, rather than a broader disregard of vaccines. Just over a third (497, 34.3%) of the respondents were concerned that the vaccine would impact their cancer treatment.

Conclusion

Overall, participants had positive attitudes toward COVID-19 vaccination and thought it was safe. Findings supported the role of health professionals and cancer organisations as trusted information providers and calls for more, credible information to help people with cancer make informed decisions about the COVID-19 vaccine.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
13.
Zurück zum Zitat World Health Organization & United Nations Children's Fund (UNICEF) (2021). Data for action: achieving high uptake of COVID-19 vaccines: gathering and using data on the behavioural and social drivers of vaccination: a guidebook for immunization programmes and implementing partners: interim guidance. https://apps.who.int/iris/handle/10665/339452. Accessed May 2022. World Health Organization & United Nations Children's Fund (UNICEF) (2021). Data for action: achieving high uptake of COVID-19 vaccines: gathering and using data on the behavioural and social drivers of vaccination: a guidebook for immunization programmes and implementing partners: interim guidance. https://​apps.​who.​int/​iris/​handle/​10665/​339452. Accessed May 2022.
14.
Zurück zum Zitat Thorne S (2016) Interpretive description: qualitative research for applied practice. Routledge, New YorkCrossRef Thorne S (2016) Interpretive description: qualitative research for applied practice. Routledge, New YorkCrossRef
Metadaten
Titel
Drivers and barriers to COVID-19 vaccination in Australians with cancer
verfasst von
Christie Allan
Amelia Hyatt
Amanda Appathurai
Megan Crane
Chhay Lim
Rachel Woolstencroft
Monica A. Slavin
Amanda Piper
Danielle Spence
Benjamin W. Teh
Publikationsdatum
01.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2023
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-023-07942-w

Weitere Artikel der Ausgabe 8/2023

Supportive Care in Cancer 8/2023 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.